{
  "main_header": {
    "sid": 982753,
    "name": "Ambalal Sarabhai",
    "stock_name": "Ambalal Sarabhai",
    "full_name": "Ambalal Sarabhai Enterprises Ltd",
    "name_url": "stocks-analysis/ambalal-sarabhai",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "38.55",
    "chg": 1.9,
    "chgp": "5.18%",
    "dir": 1,
    "prev_price": "36.65",
    "mcapval": "295.42 Cr",
    "mcap": "Micro Cap",
    "scripcode": 500009,
    "symbol": "AMBASARABH",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE432A01017",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "01:24 AM",
    "bse_nse_vol": "52.49 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ambalal-sarabhai-982753-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Ambalal Sarabhai Enterprises Faces Persistent Volatility Amidst Underperformance in Pharmaceuticals Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ambalal-sarabhai-enterprises-hits-52-week-low-amid-ongoing-stock-decline-3-1403469",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AmbalalSarabhai_priceRelatedfactors_681659.png",
        "date": "2025-03-17 13:08:03",
        "description": "Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low amid a three-day losing streak. The company has seen a 24.31% decline over the past year, despite a substantial profit increase, and is trading below key moving averages, indicating ongoing challenges."
      },
      {
        "title": "Ambalal Sarabhai Enterprises Adjusts Valuation Amidst Mixed Industry Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ambalal-sarabhai-enterprises-valuation-grade-changes-from-expensive-to-fair-amid-stock-volatility-1200385",
        "imagepath": "",
        "date": "2025-03-05 08:00:55",
        "description": "Ambalal Sarabhai Enterprises, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 35.99, slightly down from the previous close of 36.43. Over the past year, Ambalal Sarabhai has faced challenges, with a stock return of -34.91%, contrasting with a modest -1.19% return from the Sensex.\n\nKey financial metrics reveal a PE ratio of 19.40 and an EV to EBITDA ratio of 35.86, indicating a competitive positioning within its industry. The company's return on equity (ROE) is reported at 9.49%, while the return on capital employed (ROCE) is at 4.97%. In comparison to its peers, Ambalal Sarabhai's valuation metrics present a mixed picture. For instance, Shree Ganesh Rem is positioned at a higher valuation level, while Kopran and Anuh Pharma show more attractive metrics in terms of PE and EV to EBITDA ratios.\n\nOverall, the evaluatio..."
      },
      {
        "title": "Ambalal Sarabhai Enterprises Faces Ongoing Challenges Amid Broader Market Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ambalal-sarabhai-enterprises-hits-52-week-low-amid-ongoing-stock-decline-2-1180737",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AmbalalSarabhai_priceRelatedfactors_566659.png",
        "date": "2025-03-04 11:38:35",
        "description": "Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, continuing a downward trend. The stock's performance over the past year has been poor, with low profitability metrics and a relatively low debt level, reflecting ongoing challenges in the current market."
      },
      {
        "title": "Ambalal Sarabhai Enterprises Faces Significant Volatility Amidst Declining Stock Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ambalal-sarabhai-enterprises-hits-new-52-week-low-amid-ongoing-decline-1173064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AmbalalSarabhai_priceRelatedfactors_562628.png",
        "date": "2025-03-03 10:36:43",
        "description": "Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today amid significant volatility. The stock has declined notably over the past two days and is trading below all key moving averages, reflecting ongoing challenges in the market."
      },
      {
        "title": "Ambalal Sarabhai Enterprises Faces Significant Volatility Amidst Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ambalal-sarabhai-enterprises-hits-52-week-low-stock-declines-6-98-to-rs-38-1140918",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/AmbalalSarabhai_priceRelatedfactors_548714.png",
        "date": "2025-02-28 10:06:14",
        "description": "Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today, reflecting significant volatility. The stock has underperformed its sector and is trading below key moving averages, indicating ongoing challenges in a competitive market. Its annual decline contrasts with the Sensex's gains."
      },
      {
        "title": "Ambalal Sarabhai Enterprises Faces Significant Volatility Amidst Sector Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ambalal-sarabhai-enterprises-hits-52-week-low-amid-ongoing-stock-decline-1111477",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/AmbalalSarabhai_priceRelatedfactors_515420.png",
        "date": "2025-02-25 12:35:19",
        "description": "Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low amid significant volatility. The stock has declined consecutively over three days and is trading below key moving averages, reflecting ongoing challenges and underperformance compared to the broader market."
      },
      {
        "title": "Ambalal Sarabhai Enterprises Reports Mixed Financial Results Amid Industry Challenges in December 2024",
        "link": "https://www.marketsmojo.com/news/result-analysis/ambalal-sarabhai-enterprises-reports-flat-performance-with-declining-profit-before-tax-in-dec24-results-1020273",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/AmbalalSarabhai_quaterlyResult_450552.png",
        "date": "2025-02-15 10:09:13",
        "description": "Ambalal Sarabhai Enterprises has released its financial results for the quarter ending December 2024, showcasing significant growth in Profit After Tax, which reached Rs 4.85 crore. However, challenges persist, including a decline in Profit Before Tax and Operating Profit, alongside increased borrowings reflected in the Debt-Equity Ratio."
      }
    ],
    "total": 32,
    "sid": "982753",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/ambalal-sarabhai-enterprises-982753"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "29-Mar-2025",
      "details": "Closure of Trading Window",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Feb-2025",
      "details": "Newspaper Publication under Regulation 30 of SEBI (LODR)",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On 14.02.2025",
      "datetime": "14-Feb-2025",
      "details": "Following matters have been discussed considered and approved by the Board of Directors in its meeting held on 14th February 2025: 1. Pursuant to Regulations 30 & 33 of Chapter IV read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 we are pleased to inform you that the Board of Directors of the Company in their meeting held on 14th February 2025 has considered approved and taken on record the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on 31st December 2024 along with Limited Review Report of Auditors thereon. In this regard please find enclosed herewith the following: A. Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on 31st December 2024; and B. Limited Review Report issued by the Statutory Auditors of the Company. Kindly take the same on your records.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ambalal Sarabhai Enterprises Faces Persistent Volatility Amidst Underperformance in Pharmaceuticals Sector

2025-03-17 13:08:03

Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low amid a three-day losing streak. The company has seen a 24.31% decline over the past year, despite a substantial profit increase, and is trading below key moving averages, indicating ongoing challenges.

Read More

Ambalal Sarabhai Enterprises Adjusts Valuation Amidst Mixed Industry Performance Metrics

2025-03-05 08:00:55

Ambalal Sarabhai Enterprises, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 35.99, slightly down from the previous close of 36.43. Over the past year, Ambalal Sarabhai has faced challenges, with a stock return of -34.91%, contrasting with a modest -1.19% return from the Sensex. Key financial metrics reveal a PE ratio of 19.40 and an EV to EBITDA ratio of 35.86, indicating a competitive positioning within its industry. The company's return on equity (ROE) is reported at 9.49%, while the return on capital employed (ROCE) is at 4.97%. In comparison to its peers, Ambalal Sarabhai's valuation metrics present a mixed picture. For instance, Shree Ganesh Rem is positioned at a higher valuation level, while Kopran and Anuh Pharma show more attractive metrics in terms of PE and EV to EBITDA ratios. Overall, the evaluatio...

Read More

Ambalal Sarabhai Enterprises Faces Ongoing Challenges Amid Broader Market Decline

2025-03-04 11:38:35

Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, continuing a downward trend. The stock's performance over the past year has been poor, with low profitability metrics and a relatively low debt level, reflecting ongoing challenges in the current market.

Read More

Ambalal Sarabhai Enterprises Faces Significant Volatility Amidst Declining Stock Performance

2025-03-03 10:36:43

Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today amid significant volatility. The stock has declined notably over the past two days and is trading below all key moving averages, reflecting ongoing challenges in the market.

Read More

Ambalal Sarabhai Enterprises Faces Significant Volatility Amidst Market Underperformance

2025-02-28 10:06:14

Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today, reflecting significant volatility. The stock has underperformed its sector and is trading below key moving averages, indicating ongoing challenges in a competitive market. Its annual decline contrasts with the Sensex's gains.

Read More

Ambalal Sarabhai Enterprises Faces Significant Volatility Amidst Sector Underperformance

2025-02-25 12:35:19

Ambalal Sarabhai Enterprises, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low amid significant volatility. The stock has declined consecutively over three days and is trading below key moving averages, reflecting ongoing challenges and underperformance compared to the broader market.

Read More

Ambalal Sarabhai Enterprises Reports Mixed Financial Results Amid Industry Challenges in December 2024

2025-02-15 10:09:13

Ambalal Sarabhai Enterprises has released its financial results for the quarter ending December 2024, showcasing significant growth in Profit After Tax, which reached Rs 4.85 crore. However, challenges persist, including a decline in Profit Before Tax and Operating Profit, alongside increased borrowings reflected in the Debt-Equity Ratio.

Read More

View All News